The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on December 05, 2025 for Docon Technologies Pvt Ltd
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.5 pts more than Nifty Microcap 250 and 6.1 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Docon Technologies Pvt Ltd, a promoter and holding company of Thyrocare (and wholly owned subsidiary of API Holdings), has disclosed the creation of a pledge on 9,69,69,696 bonus equity shares allotted to it after Thyrocare's 2:1 bonus issue on December 1, 2025. The pledge is in favor of Catalyst Trusteeship Limited as Debenture Trustee, to secure secured, unlisted, redeemable non-convertible debentures worth INR 12,000 million issued by API Holdings. While the number of encumbered shares increased from 3,23,23,232 to 9,69,69,696, the pledged percentage of Thyrocare's paid-up share capital remained unchanged at 60.93%. The encumbered shares are valued at approximately INR 45,013.33 million based on the December 2, 2025 closing price of INR 464.20.
This is an automatic, technical pledge created on bonus shares—no fresh borrowing or change in promoter financial position. The pledged percentage staying at 60.93% means no additional risk to shareholders from this event, though existing investors should note that over 60% of promoter-held shares remain encumbered, keeping refinancing and pledge-invocation risk in focus.